Isis Pharmaceuticals regulatory update

ISIP received U.S. Patent No. 5,514,788 covering ISIS 2302, an antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1). The patent claims more than 40 other antisense compounds targeted a...